Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG PET-MRI Timing for Spinal Cord Lesions
NCT04219969Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fludeoxyglucose f 18 in spinal cord neoplasm (SCT), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Standardized Uptake Value at 480 months. Started Sep 2018; status: completed.
02
Drugs
fludeoxyglucose f 18
03
Conditions
spinal cord neoplasm (SCT)
Beyond the preview
Go deeper on NCT04219969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219969.